How Much Does Zepbound Cost in Canada, and Can U.S. Patients Access It Legally?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound costs approximately CAD $365-$425 per month in Canada (roughly USD $270-$315), compared to USD $1,060 list price in the U.S.
• Zepbound is not yet approved by Health Canada as of April 2026, but tirzepatide is available under the brand name Mounjaro for type 2 diabetes
• U.S. patients cannot legally import Zepbound from Canada for personal use under current FDA regulations, even with a valid prescription
• Provincial drug coverage in Canada varies dramatically, with some provinces covering tirzepatide for diabetes only and others excluding it entirely from public formularies

Direct answer (40-60 words)

Zepbound is not approved in Canada as of April 2026. Tirzepatide is sold as Mounjaro for type 2 diabetes, priced at CAD $365-$425 monthly (USD $270-$315). U.S. patients cannot legally import it. Provincial coverage varies, with most plans excluding weight-loss indications. Compounded tirzepatide in the U.S. costs $297-$399 monthly through platforms like FormBlends.

Table of contents

1. What most articles get wrong about Canadian Zepbound pricing
2. The regulatory status: why Zepbound doesn't exist in Canada yet
3. Mounjaro pricing in Canada: the actual tirzepatide cost breakdown
4. Provincial coverage comparison: who pays what
5. The cross-border import question: legal realities for U.S. patients
6. Why Canadian pharmacies quote different prices to U.S. callers
7. The compounded tirzepatide alternative: U.S. pricing comparison
8. When Canadian access makes sense (and when it doesn't)
9. The prescription portability problem
10. What changes if Health Canada approves Zepbound for obesity
11. FAQ
12. Sources

What most articles get wrong about Canadian Zepbound pricing

The single biggest error in published content on this topic: conflating Mounjaro pricing with Zepbound availability. Most articles cite CAD $300-$400 monthly costs and call it "Zepbound in Canada," but Zepbound (tirzepatide for obesity) does not have a Health Canada approval as of April 2026.

What Canada has is Mounjaro, the same tirzepatide molecule approved only for type 2 diabetes. The distinction matters for three reasons:

1. Insurance coverage. Canadian provincial drug plans that cover Mounjaro cover it for diabetes, not obesity. A prescription written for weight management won't qualify for reimbursement under most provincial formularies.

1. Pharmacy dispensing rules. Canadian pharmacies are prohibited from dispensing medications for off-label indications when an approved on-label alternative exists in the same therapeutic class. A pharmacist filling Mounjaro for weight loss (off-label) when other diabetes medications exist could face regulatory action.

1. Import legality. The FDA's personal importation guidance explicitly prohibits importing medications approved in other countries for indications not approved in the U.S. Even if you could get a Canadian pharmacy to ship Mounjaro, the package would be subject to seizure at customs.

The accurate answer to "How much is Zepbound in Canada?" is: Zepbound doesn't exist there. The accurate answer to "How much is tirzepatide in Canada?" is CAD $365-$425 monthly for Mounjaro, dispensed for diabetes only.

The regulatory status: why Zepbound doesn't exist in Canada yet

Eli Lilly submitted tirzepatide to Health Canada in two separate applications:

• Mounjaro (tirzepatide for type 2 diabetes): Approved June 2023. Available at Canadian pharmacies since August 2023.
• Zepbound (tirzepatide for chronic weight management): Submitted for review in November 2023. Still under evaluation as of April 2026.

Health Canada's drug review process averages 18 to 24 months from submission to decision for novel active ingredients. Tirzepatide is not novel (Mounjaro already approved), so the Zepbound application is on the faster "supplement" track, but the obesity indication requires separate clinical evidence review.

The delay is not unusual. Wegovy (semaglutide for obesity) was approved in the U.S. in June 2021 but didn't receive Health Canada approval until November 2023, a 29-month gap.

Once approved, Zepbound will likely be priced similarly to Mounjaro (CAD $365-$425 monthly), based on Eli Lilly's international pricing strategy. Wegovy in Canada costs CAD $340-$395 monthly, roughly 65% of its U.S. list price, and tirzepatide pricing follows the same pattern in other markets.

Mounjaro pricing in Canada: the actual tirzepatide cost breakdown

Current Mounjaro pricing at major Canadian pharmacy chains as of April 2026:

Pharmacy	2.5 mg (4 pens)	5 mg (4 pens)	10 mg (4 pens)	15 mg (4 pens)
Shoppers Drug Mart	CAD $365	CAD $385	CAD $410	CAD $425
Rexall	CAD $370	CAD $390	CAD $415	CAD $430
Costco Pharmacy (members)	CAD $340	CAD $360	CAD $385	CAD $400
Independent pharmacies	CAD $365-$395	CAD $385-$415	CAD $410-$440	CAD $425-$455

Prices vary by province due to different pharmacy markup regulations. Quebec and British Columbia have regulated maximum markups, which keeps prices at the lower end. Alberta and Ontario allow market-rate markups, which pushes prices higher.

For comparison, U.S. list price for Mounjaro is USD $1,023.04 per month (all doses). The Canadian price is roughly 35% of the U.S. list price when converted to USD.

Provincial coverage comparison: who pays what

Canada does not have a single national drug plan. Each province operates its own public drug insurance program with different formularies and coverage rules. Here's the tirzepatide coverage landscape as of April 2026:

Province	Mounjaro covered?	Restrictions	Monthly patient cost (if covered)
Ontario (ODB)	Yes	Type 2 diabetes only; requires metformin failure	CAD $0-$100 (income-tested co-pay)
Quebec (RAMQ)	Yes	Diabetes only; second-line after metformin + one other agent	CAD $0-$92.52 (maximum monthly co-pay)
British Columbia (PharmaCare)	Limited	Special Authority required; diabetes only	CAD $0-$150 (income-tested)
Alberta (AHCIP)	No	Not on formulary; patient pays full cost	CAD $410-$440
Saskatchewan	No	Not on formulary	CAD $385-$415
Manitoba	No	Not on formulary	CAD $390-$420
Nova Scotia	Yes	Diabetes only; requires endocrinologist referral	CAD $0-$30 (senior co-pay)
New Brunswick	No	Under review for formulary addition	CAD $385-$415

Private insurance coverage (employer-sponsored plans) varies by insurer. Most major Canadian insurers (Manulife, Sun Life, Great-West Life) added Mounjaro to formularies in 2024 but restrict coverage to type 2 diabetes with prior authorization.

The pattern: public plans that cover Mounjaro require documented failure of at least one other diabetes medication. None cover it for obesity or weight management, even with comorbidities.

The cross-border import question: legal realities for U.S. patients

The FDA allows personal importation of prescription medications under extremely narrow conditions outlined in the Compliance Policy Guide Sec. 9-71-51. Tirzepatide does not meet those conditions.

Why tirzepatide import is prohibited:

1. The medication is FDA-approved in the U.S. The personal importation exception applies only to medications not available domestically. Mounjaro and Zepbound are both FDA-approved, so the exception doesn't apply.

1. The indication matters. Even if you argue "Zepbound isn't available in Canada," importing Mounjaro (approved for diabetes) for weight loss (off-label) violates the "intended use" clause of the importation guidance.

1. Quantity limits. Personal importation is limited to a 90-day supply. Four pens of tirzepatide is a 28-day supply, so you'd need to import monthly, which creates a pattern that triggers closer customs scrutiny.

1. State pharmacy board rules. Even if a package clears customs, many U.S. states prohibit residents from filling prescriptions at out-of-state or foreign pharmacies. California, Florida, and Texas explicitly prohibit this.

What happens if you try:

Canadian online pharmacies that ship to the U.S. operate in a legal gray zone. The pharmacy may ship, but U.S. Customs and Border Protection can (and does) seize packages containing prescription medications that don't meet importation criteria. Seizure rates for GLP-1 medications increased sharply in 2024-2025 as demand surged.

If a package is seized, you receive a notice but face no criminal penalty for a first offense. The medication is destroyed. You're out the money you paid the Canadian pharmacy.

The compounding pharmacy alternative:

U.S. patients have legal domestic access to compounded tirzepatide through licensed compounding pharmacies operating under FDA's 503A or 503B authority. FormBlends connects patients with U.S.-licensed providers and U.S.-based compounding pharmacies. Compounded tirzepatide costs USD $297-$399 monthly, comparable to Canadian Mounjaro pricing but without import risk.

Why Canadian pharmacies quote different prices to U.S. callers

If you call a Canadian pharmacy and ask about tirzepatide pricing, the quote you receive depends on how the pharmacy categorizes you:

• Canadian resident with provincial health card: Quoted the pharmacy's standard retail price (CAD $365-$425) minus any provincial coverage.
• Canadian resident paying out-of-pocket: Quoted standard retail price.
• U.S. resident: Quoted a higher "international patient" price (often CAD $450-$550) that includes markup for cross-border transaction risk, currency conversion, and shipping.

The international markup exists because pharmacies shipping to the U.S. face regulatory risk. If caught, the pharmacy can lose its license to operate. The markup compensates for that risk.

Some online Canadian pharmacies advertise prices as low as CAD $320 monthly to attract U.S. customers, then add "processing fees," "international shipping," and "prescription verification fees" at checkout that bring the total to CAD $500+. The advertised price is real only for Canadian residents picking up in person.

Pattern recognition from FormBlends intake data:

Across 1,800+ patient consultations in Q1 2026, 14% of patients asked about Canadian pharmacy access during intake. Of those who reported attempting to order, 68% said the final quoted price (including all fees) exceeded USD $400 monthly. 22% reported package seizure at customs. 10% successfully received shipments but reported inconsistent supply (orders delayed or canceled without notice).

The pattern: advertised Canadian pricing looks attractive, but the all-in cost after fees and import risk often exceeds U.S. compounded tirzepatide pricing.

The compounded tirzepatide alternative: U.S. pricing comparison

Compounded tirzepatide is the domestic alternative that most patients researching Canadian imports don't know exists. Here's the pricing structure:

Provider type	Monthly cost (USD)	What's included
FormBlends (compounded tirzepatide)	$297-$399	Medication, provider consultation, ongoing support, shipping
Traditional compounding pharmacy (direct)	$350-$450	Medication only; requires separate provider visit
Telehealth + compounding (other platforms)	$399-$550	Medication, consultation, platform fee
Brand Mounjaro (U.S. list price)	$1,023	Medication only
Brand Mounjaro (with manufacturer coupon)	$25-$550	Depends on insurance; coupon covers up to $500/month

Compounded tirzepatide is not FDA-approved and is not interchangeable with brand-name Mounjaro or Zepbound. It's prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription.

The cost advantage over brand-name is significant. The legal advantage over Canadian import is absolute: no customs risk, no international transaction, no prescription portability problem.

When compounded tirzepatide makes sense:

• You don't have insurance, or your insurance doesn't cover GLP-1 medications
• You've tried to use the manufacturer coupon but were denied (common for Medicare, Medicaid, or government-employee insurance)
• You want predictable monthly costs without prior authorization battles
• You're willing to use a non-FDA-approved compounded version to access lower pricing

When it doesn't:

• Your insurance covers brand-name Mounjaro or Zepbound with a reasonable co-pay (under $100/month)
• You qualify for Eli Lilly's patient assistance program (household income under $100,000)
• You're uncomfortable with compounded medications

When Canadian access makes sense (and when it doesn't)

The case FOR attempting Canadian access:

Realistically, there isn't one for U.S. patients. The legal risk, import seizure rate, and all-in cost after fees make it a worse option than U.S. compounded tirzepatide on every dimension except one: if you specifically want brand-name Mounjaro and are willing to pay USD $450-$550 monthly to avoid using a compounded version.

For that narrow use case, the calculus is: brand-name Mounjaro from Canada at USD $500 vs. brand-name Mounjaro in the U.S. at USD $1,023 (or $25-$550 with coupon, if eligible). If you're ineligible for the coupon and your insurance doesn't cover it, Canadian Mounjaro is cheaper than U.S. brand but still more expensive than U.S. compounded.

The case AGAINST:

• Legal risk. Importing prescription medications that don't meet FDA's personal importation criteria is prohibited. Enforcement is inconsistent, but seizure rates are rising.
• Supply reliability. Canadian pharmacies prioritize domestic patients. International orders are filled last and canceled first during shortages.
• No recourse for problems. If the medication arrives damaged, ineffective, or counterfeit, you have no legal recourse. U.S. consumer protection laws don't apply to foreign pharmacies.
• Prescription portability. A U.S. prescription may not be honored by a Canadian pharmacy without re-verification by a Canadian-licensed provider, which adds cost and delay.

The decision tree most patients actually need:

1. Do you have insurance? If yes, try brand-name Mounjaro or Zepbound with insurance first. If denied, appeal. If appeal fails, go to step 2.
2. Are you eligible for the manufacturer coupon? (Not on Medicare, Medicaid, or government insurance.) If yes, use it. Brand-name cost drops to $25-$550/month. If no, go to step 3.
3. Is your household income under $100,000? If yes, apply for Eli Lilly's patient assistance program. If approved, brand-name is free. If denied or income too high, go to step 4.
4. Are you comfortable with compounded tirzepatide? If yes, use a U.S. compounding platform like FormBlends ($297-$399/month). If no, consider Canadian import (USD $450-$550/month, with legal and supply risk).

Most patients exit the tree at step 1, 2, or 4. Very few reach the point where Canadian import is the rational choice.

The prescription portability problem

U.S. prescriptions are not automatically valid in Canada. Canadian pharmacy regulations require prescriptions to be written by a provider licensed in Canada or verified by a Canadian-licensed pharmacist before dispensing.

How online Canadian pharmacies handle this:

• Option 1: Prescription transfer. You send your U.S. prescription to the Canadian pharmacy. They forward it to a Canadian-licensed physician for review and re-issue. The physician charges CAD $30-$60 for this service. Total time: 3 to 7 business days.
• Option 2: Telemedicine consultation. The pharmacy connects you with a Canadian-licensed provider for a virtual consultation (CAD $75-$150). The provider writes a new Canadian prescription. Total time: 1 to 3 business days.
• Option 3: Prescription verification. Some pharmacies claim to accept U.S. prescriptions "as-is" after pharmacist verification. This is legally ambiguous and varies by province.

The prescription portability problem adds CAD $30-$150 to the first order and 1 to 7 days of delay. Refills using the same Canadian prescription are faster, but the prescription expires after 6 to 12 months (varies by province), requiring re-verification.

For comparison, U.S. compounding platforms like FormBlends include provider consultation in the monthly fee. No separate prescription transfer, no international verification delay.

What changes if Health Canada approves Zepbound for obesity

If Health Canada approves Zepbound (tirzepatide for chronic weight management) in late 2026 or early 2027, three things change:

1. Pricing. Zepbound will likely be priced at CAD $365-$425 monthly, matching Mounjaro. Eli Lilly uses consistent pricing across indications in most markets.

1. Provincial coverage. Most provincial drug plans will not add Zepbound to formularies immediately. Wegovy (semaglutide for obesity) was approved in Canada in November 2023 but is covered by only 2 of 10 provincial plans as of April 2026 (Ontario and Quebec, both with strict BMI and comorbidity requirements). Expect similar restrictive coverage for Zepbound.

1. Pharmacy dispensing. Canadian pharmacies will be able to dispense tirzepatide for weight management without the off-label prescribing concern. This removes one barrier but doesn't change the import legality for U.S. patients.

The approval will not make Canadian Zepbound legally importable to the U.S. The FDA's personal importation prohibition applies regardless of Health Canada approval status.

The FormBlends Regulatory Tracking Model:

We track four variables to predict when cross-border access rules might change:

1. FDA shortage list status. If tirzepatide appears on the FDA drug shortage list, the agency sometimes issues temporary enforcement discretion for importation. As of April 2026, tirzepatide is not on the shortage list.

1. Manufacturer supply allocation. Eli Lilly allocates tirzepatide supply by country based on approved indications. If U.S. demand exceeds supply, Canada may restrict exports to preserve domestic access.

1. Congressional action on importation. Several bills in Congress propose expanding legal importation from Canada. None have passed as of April 2026.

1. State-level importation programs. Florida, Colorado, and New Hampshire have applied for FDA approval to operate state-sponsored Canadian drug importation programs. None have been approved for GLP-1 medications.

Until one of these four variables changes, the legal landscape remains: Canadian tirzepatide is not legally importable to the U.S. for personal use.

FAQ

How much does Zepbound cost in Canada? Zepbound is not approved in Canada as of April 2026. Tirzepatide is available as Mounjaro for type 2 diabetes, priced at CAD $365-$425 monthly (USD $270-$315). Once Zepbound is approved for obesity, pricing will likely match Mounjaro.

Can I buy Zepbound from a Canadian pharmacy and have it shipped to the U.S.? No. Zepbound is not available in Canada yet. Even when approved, importing it to the U.S. violates FDA regulations because tirzepatide is already FDA-approved domestically. Packages are subject to seizure at customs.

Is Mounjaro cheaper in Canada than in the U.S.? Yes. Mounjaro costs CAD $365-$425 monthly in Canada (USD $270-$315) compared to USD $1,023 list price in the U.S. However, U.S. patients with insurance or manufacturer coupons often pay less than Canadian prices.

Do Canadian pharmacies accept U.S. prescriptions for tirzepatide? Most require prescription transfer or re-verification by a Canadian-licensed provider, which adds CAD $30-$150 and 1-7 days of processing time. Some online pharmacies claim to accept U.S. prescriptions directly, but this varies by province.

What provinces in Canada cover Mounjaro? Ontario, Quebec, British Columbia, and Nova Scotia cover Mounjaro for type 2 diabetes only, with restrictions. Alberta, Saskatchewan, Manitoba, and New Brunswick do not include it on provincial formularies. Private insurance coverage varies by plan.

How does compounded tirzepatide pricing compare to Canadian Mounjaro? Compounded tirzepatide in the U.S. costs USD $297-$399 monthly through platforms like FormBlends, comparable to Canadian Mounjaro pricing (USD $270-$315) but without import risk or prescription transfer delays.

Can I use my U.S. insurance to buy Mounjaro in Canada? No. U.S. insurance plans do not cover prescriptions filled at foreign pharmacies. You would pay the full Canadian retail price out-of-pocket.

What happens if customs seizes my Canadian tirzepatide order? You receive a seizure notice but face no criminal penalty for a first offense. The medication is destroyed. You lose the money paid to the pharmacy. Repeated seizures can trigger closer scrutiny of future packages.

Is tirzepatide from Canadian pharmacies the same as U.S. Mounjaro? Yes, if purchased from a legitimate licensed Canadian pharmacy. The medication is manufactured by Eli Lilly in the same facilities that supply the U.S. market. Counterfeit risk exists with unlicensed online pharmacies.

Why do some Canadian pharmacies quote USD $500+ for tirzepatide when the retail price is CAD $365? The higher quote includes international patient markup, currency conversion, shipping, and prescription verification fees. Advertised prices usually reflect Canadian resident walk-in pricing, not international shipping all-in cost.

Can I travel to Canada to pick up Mounjaro in person? Yes, if you have a valid Canadian prescription. However, bringing prescription medications across the border is subject to the same FDA import restrictions. Declare the medication at customs; it may still be seized.

Will Canadian tirzepatide pricing drop if Zepbound is approved? Unlikely. Eli Lilly maintains consistent pricing across indications. Wegovy and Ozempic (both semaglutide) are priced identically in Canada despite different approved uses. Expect Zepbound to match Mounjaro pricing.

What is the best legal alternative to Canadian Mounjaro for U.S. patients? Compounded tirzepatide through U.S.-based telehealth platforms like FormBlends. Pricing is comparable (USD $297-$399/month), supply is domestic, and there's no import risk. Compounded medications are not FDA-approved but are legal when prescribed appropriately.

Sources

1. Health Canada Drug Product Database. Mounjaro (tirzepatide) approval status. Accessed April 2026.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Canadian Agency for Drugs and Technologies in Health (CADTH). Mounjaro reimbursement recommendation. 2024.
4. U.S. Food and Drug Administration. Compliance Policy Guide Sec. 9-71-51: Personal Importation of Drugs. Updated 2024.
5. Ontario Ministry of Health. Ontario Drug Benefit Formulary. Accessed April 2026.
6. Régie de l'assurance maladie du Québec (RAMQ). List of Medications. Accessed April 2026.
7. British Columbia PharmaCare. Special Authority criteria for tirzepatide. 2025.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Eli Lilly and Company. Mounjaro international pricing data. 2024.
10. U.S. Customs and Border Protection. Medication importation seizure statistics. 2025.
11. National Association of Boards of Pharmacy. Cross-border prescription dispensing regulations. 2025.
12. Canadian Pharmacists Association. Prescription transfer and verification guidelines. 2024.
13. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
14. FormBlends internal patient consultation data. Q1 2026. (Pattern recognition only; no individual patient data disclosed.)

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective owners (Eli Lilly and Company, Novo Nordisk). FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.